Evidence-based, high-impact
software as medicine.
Click’s platform can target any disease, symptom or side effect with an underlying neurological or behavioral component, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.
CT-152
Rejoyn
Indication
Major Depressive Disorder (MDD)
Collaborator
Phase
Launch- AspyreRx
AspyreRx
AspyreRx™
Indication
Type 2 Diabetes
Collaborator
Phase
FDA Cleared - CT-132
CT-132
Indication
Episodic Migraine
Collaborator
Phase
Regulatory Review - CT-155
CT-155
Indication
Schizophrenia
Collaborator
Phase
Phase 3: Pivotal - CT-156
CT-156
Indication
Schizophrenia
Collaborator
Phase
Phase 2: Dev/Pilot - CT-102
CT-102
Indication
Opioid Use Disorder (OUD)
Collaborator
Phase
Phase 2: Dev/Pilot - CT-133
CT-133
Indication
Multiple Sclerosis (MS)
Collaborator
Phase
Phase 1: Discovery - CT-171
CT-171
Indication
Atopic Dermatitis
Collaborator
Phase
Phase 1: Discovery - CT-181
CT-181
Indication
Obesity
Collaborator
Phase
Phase 1: Discovery - CT-191
CT-191
Indication
Oncology
Collaborator
Phase
Phase 1: Discovery - CT-141
CT-141
Clickadian™
Indication
Insomnia
Collaborator
Phase
Phase 1: Discovery - CT-111
CT-111
Clickheart™
Indication
Acute Coronary Syndrome
Collaborator
Phase
Phase 1: Discovery
Product
Indication
Collaborator
Phase
CT-152
Rejoyn
Major Depressive Disorder (MDD)
Launch- AspyreRx
AspyreRx
AspyreRx™
Type 2 DiabetesFDA Cleared - CT-132
CT-132
Episodic MigraineRegulatory Review - CT-155
CT-155
Schizophrenia
Phase 3: Pivotal - CT-156
CT-156
SchizophreniaPhase 2: Dev/Pilot - CT-102
CT-102
Opioid Use Disorder (OUD)Phase 2: Dev/Pilot - CT-133
CT-133
Multiple Sclerosis (MS)Phase 1: Discovery - CT-171
CT-171
Atopic DermatitisPhase 1: Discovery - CT-181
CT-181
ObesityPhase 1: Discovery - CT-191
CT-191
OncologyPhase 1: Discovery - CT-141
CT-141
Clickadian™
InsomniaPhase 1: Discovery - CT-111
CT-111
Clickheart™
Acute Coronary SyndromePhase 1: Discovery
Medicine just got a digital upgrade: Software-Enhanced Drugs™
Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, to deliver added clinical benefit to patients compared to drug alone.
Contact
Q&A
Stay up to date with news and updates
CT-155
Indication
Schizophrenia
Collaborator
Phase
Phase 3: PivotalCT-155 is an investigational prescription digital therapeutic designed to treat the negative symptoms of schizophrenia for use adjunctive to standard of care pharmaceutical therapy. CT-155 received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), as announced in January 2024.
To date, the CT-155 program has achieved all development milestones and generated supportive data across multiple clinical learning studies, leading to the initiation of the CONVOKE registrational clinical trial, in May 2023.
CT-155 is the first investigational PDT developed as part of the collaboration between Click Therapeutics and Boehringer Ingelheim, which has been in effect since September 2020. The collaboration has since expanded to include an additional investigational prescription-based digital therapeutic for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes, which was announced in December 2022.
Gaps in care for those living with schizophrenia
Schizophrenia is one of the 15 leading causes of disability worldwide, which impacts around 24 million people today.1,2 It is a serious mental health condition that alters a person’s perception of reality and impacts how they think, feel, and behave.3 Schizophrenia is also associated with the highest worldwide societal cost per patient of all mental health disorders.4
Currently, available antipsychotic medications for schizophrenia are indicated for positive symptoms, such as hallucinations, disorganized speech, and behavior agitation. However, a significant contributor to the profound burden associated with schizophrenia is negative symptoms, which are strong predictors of cognitive impairment5 and are not effectively addressed by the standard of care antipsychotic or any other medication.6,7 Thus, there is great promise in the development of PDTs to alleviate negative symptoms, offering healthcare providers and patients a means to tackle this severe mental illness. PDTs also have the potential to reduce the personal and socio-economic burden of schizophrenia. Currently, no approved pharmacotherapies or medical devices are available to treat the negative symptoms of schizophrenia that are at the root of significant day-to-day functional impairment for these patients.
Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia
A positive DWA was established between participants and CT-155 beta within 3 weeks. The second 7-week study showed maintenance of the DWA to the end of the study. Results support the establishment and maintenance of a DWA between adults with ENS of schizophrenia and a beta version of CT-155.
CT-155
Indication
Schizophrenia
Collaborator
Phase
Phase 3: PivotalCT-155 is an investigational prescription digital therapeutic designed to treat the negative symptoms of schizophrenia for use adjunctive to standard of care pharmaceutical therapy. CT-155 received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), as announced in January 2024.
To date, the CT-155 program has achieved all development milestones and generated supportive data across multiple clinical learning studies, leading to the initiation of the CONVOKE registrational clinical trial, in May 2023.
CT-155 is the first investigational PDT developed as part of the collaboration between Click Therapeutics and Boehringer Ingelheim, which has been in effect since September 2020. The collaboration has since expanded to include an additional investigational prescription-based digital therapeutic for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes, which was announced in December 2022.
Gaps in care for those living with schizophrenia
Schizophrenia is one of the 15 leading causes of disability worldwide, which impacts around 24 million people today.1,2 It is a serious mental health condition that alters a person’s perception of reality and impacts how they think, feel, and behave.3 Schizophrenia is also associated with the highest worldwide societal cost per patient of all mental health disorders.4
Currently, available antipsychotic medications for schizophrenia are indicated for positive symptoms, such as hallucinations, disorganized speech, and behavior agitation. However, a significant contributor to the profound burden associated with schizophrenia is negative symptoms, which are strong predictors of cognitive impairment5 and are not effectively addressed by the standard of care antipsychotic or any other medication.6,7 Thus, there is great promise in the development of PDTs to alleviate negative symptoms, offering healthcare providers and patients a means to tackle this severe mental illness. PDTs also have the potential to reduce the personal and socio-economic burden of schizophrenia. Currently, no approved pharmacotherapies or medical devices are available to treat the negative symptoms of schizophrenia that are at the root of significant day-to-day functional impairment for these patients.
Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia
A positive DWA was established between participants and CT-155 beta within 3 weeks. The second 7-week study showed maintenance of the DWA to the end of the study. Results support the establishment and maintenance of a DWA between adults with ENS of schizophrenia and a beta version of CT-155.